Director, Applied AI Architect
Immunic Therapeutics
Summary
We are seeking an Applied AI Architect to shape the company's technology landscape across R&D, Commercial, and G&A functions.
Job description
Summary
We are seeking an Applied AI Architect to shape the company's technology landscape across R&D, Commercial, and G&A functions.
Reporting to the Chief Data & Digital Officer, you will act as both a strategic thinker and hands-on builder, defining Immunic's technology architecture and AI foundation, driving the roadmap for agentic systems, and partnering closely with teams across the enterprise.
You will join us at an important point before Phase 3 data readout and help shape the technology foundation for the enterprise. The ideal candidate combines a product mindset with hands-on execution.
Responsibilities
- Define and maintain Immunic's AI architecture, establishing scalable standards and design patterns across business groups and functions.
- Lead discovery with business teams to identify, qualify, and prioritize use cases tied to outcomes.
- Understand modern AI systems, frontier LLM models, agentic applications, model evaluation, retrieval, or enterprise AI workflows.
- Partner with Research, Development, Medical, Commercial, and G&A functions to bridge business needs and technical execution, guide platform selection, integration, and buy-versus-build decisions.
- Establish practical guardrails and repeatable patterns that enable teams to move quickly and safely.
- Provide technical leadership and mentorship to AI engineers and cross-functional stakeholders.
- Monitor technology spend (FinOps) and optimize AI-related compute and token usage as adoption scales, adapting architectural approaches to an evolving AI cost landscape.
Qualifications & Education
- Bachelor's degree in Computer Science, Engineering, or a related technical field or equivalent experience. Master's degree preferred.
- 8+ years of enterprise architecture, AI engineering, or a related technical discipline, including proficiency with AI coding agents and workflows.
- Demonstrated experience building agentic AI solutions in a regulated environment.
- Strong knowledge of cloud infrastructure and networking, enterprise data platforms, and system architecture, with the ability to collaborate effectively with business stakeholder teams.
- Excellent communication and influencing skills; ability to operate strategically while being hands-on.
- Willingness and ability to travel approximately 25–40% of the time, including internationally.
- Experience in evaluating emerging AI technologies, frameworks, and platforms preferred.
Requirements
- Bachelor's degree in Computer Science, Engineering, or a related technical field or equivalent experience
- Master's degree preferred
- 8+ years of enterprise architecture, AI engineering, or a related technical discipline
- Proficiency with AI coding agents and workflows
- Demonstrated experience building agentic AI solutions in a regulated environment
- Strong knowledge of cloud infrastructure and networking, enterprise data platforms, and system architecture
- Excellent communication and influencing skills
- Willingness and ability to travel approximately 25–40% of the time, including internationally
- Experience in evaluating emerging AI technologies, frameworks, and platforms preferred
Benefits
- Equity
- Bonus
Company overview
Immunic Therapeutics (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for chronic inflammatory and autoimmune diseases, with a primary focus on neurologic conditions such as multiple sclerosis (MS). Headquartered in New York City with additional operations in Gräfelfing, Germany, the company is dedicated to advancing a clinical pipeline of orally administered, small molecule therapeutics. Its lead program, vidofludimus calcium (IMU-838), is a first-in-class oral therapy that combines neuroprotective effects through nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral properties via selective dihydroorotate dehydrogenase (DHODH) inhibition. Vidofludimus calcium is currently in Phase 3 clinical trials (ENSURE program) for relapsing multiple sclerosis, with top-line data expected by the end of 2026, and has demonstrated promising therapeutic activity in Phase 2 trials for both relapsing-remitting and progressive MS. The company's pipeline also includes earlier-stage programs, such as IMU-856 targeting gastrointestinal diseases and IMU-381 for gastrointestinal applications. Founded in 2016, Immunic employs approximately 51-200 people and is transitioning toward becoming a fully integrated commercial-stage biotechnology company.